ACADIA Pharmaceuticals - ACAD Stock Forecast, Price & News

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last year. There are currently 2 sell ratings, 6 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ACAD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ACAD, but not buy additional shares or sell existing shares.
View ACAD analyst ratings or view top-rated stocks.

17 Wall Street research analysts have issued 1-year price targets for ACADIA Pharmaceuticals' stock. Their ACAD share price forecasts range from $12.00 to $33.00. On average, they predict the company's stock price to reach $21.44 in the next twelve months. This suggests a possible upside of 15.3% from the stock's current price.
View analysts price targets for ACAD or view top-rated stocks among Wall Street analysts.

ACADIA Pharmaceuticals' stock was trading at $15.92 at the beginning of 2023. Since then, ACAD shares have increased by 16.8% and is now trading at $18.60.
View the best growth stocks for 2023 here.

ACADIA Pharmaceuticals saw a increase in short interest in March. As of March 15th, there was short interest totaling 8,500,000 shares, an increase of 5.7% from the February 28th total of 8,040,000 shares. Based on an average trading volume of 1,530,000 shares, the short-interest ratio is currently 5.6 days. Approximately 5.3% of the company's stock are short sold.
View ACADIA Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our ACAD earnings forecast.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) released its quarterly earnings data on Monday, February, 27th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.25) by $0.01. The biopharmaceutical company earned $136.49 million during the quarter, compared to analyst estimates of $135.18 million. ACADIA Pharmaceuticals had a negative trailing twelve-month return on equity of 50.65% and a negative net margin of 41.76%. The firm's revenue for the quarter was up 4.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.27) EPS.

ETFs with the largest weight of ACADIA Pharmaceuticals (NASDAQ:ACAD) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), Psyk Etf (PSYK), First Trust NYSE Arca Biotechnology Index Fund (FBT), Invesco Dynamic Biotechnology & Genome ETF (PBE), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Products ETF (BBP), SPDR S&P Biotech ETF (XBI) and Principal Healthcare Innovators ETF (BTEC).

ACADIA Pharmaceuticals updated its FY 2023 earnings guidance on Monday, February, 27th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $520.00 million-$550.00 million, compared to the consensus revenue estimate of $569.16 million.

8 employees have rated ACADIA Pharmaceuticals Chief Executive Officer Steve Davis on Glassdoor.com. Steve Davis has an approval rating of 88% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other ACADIA Pharmaceuticals investors own include Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Sarepta Therapeutics (SRPT), Pfizer (PFE), Tesla (TSLA), Alibaba Group (BABA), Amarin (AMRN), Advanced Micro Devices (AMD) and Exelixis (EXEL).

ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACAD."

ACADIA Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Price T Rowe Associates Inc. MD (2.64%), First Trust Advisors LP (1.78%), Morgan Stanley (1.70%), Geode Capital Management LLC (1.42%), JPMorgan Chase & Co. (1.29%) and Norges Bank (1.21%). Insiders that own company stock include Austin D Kim, Austin D Kim, Brendan Teehan, Elena Ridloff, James Kihara, James M Daly, Laura Brege, Mark C Schneyer, Michael J Yang, Srdjan R Stankovic, Srdjan R Stankovic and Stephen Davis.
View institutional ownership trends.

Shares of ACAD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ACAD stock can currently be purchased for approximately $18.60.

ACADIA Pharmaceuticals (NASDAQ:ACAD) has a market capitalization of $3.02 billion and generates $517.23 million in revenue each year. The biopharmaceutical company earns $-215,980,000.00 in net income (profit) each year or ($1.34) on an earnings per share basis.

The company employs 514 workers across the globe.

ACADIA Pharmaceuticals' mailing address is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. The official website for the company is www.acadia-pharm.com. The biopharmaceutical company can be reached via phone at (858) 558-2871, via email at ir@acadia-pharm.com, or via fax at 858-558-2872.